InvestorsHub Logo
Followers 0
Posts 46
Boards Moderated 0
Alias Born 07/15/2006

Re: rx7171 post# 1064

Sunday, 11/05/2006 9:41:25 AM

Sunday, November 05, 2006 9:41:25 AM

Post# of 7735
Bob .. Reading the PR and knowing what we now know , things seem to be falling in place . I've always contended that the extra shelf shares voted on at the annual meeting were/are intended for Mercks buy in .
**************************************************************
Menlo Park, CA – July 18, 2005 – Geron Corporation (Nasdaq: GERN) announced today it has entered into a collaboration and license agreement with Merck & Co., Inc. (NYSE: MRK) to develop a cancer vaccine targeting telomerase utilizing Merck’s expertise in vaccine technologies.

Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Merck has also agreed to ACQUIRE EQUITY in Geron at a future date as part of Geron’s NEXT ROUND of financing. Additional financial terms were not disclosed.
( emphasis mine )
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News